Charity Registration Number 1189246
British Psoriatic Arthritis Consortium
Report and Accounts
31 March 2024
British Psoriatic Arthritis Consortium
Report and accounts for the year ended 31 March 2024
Contents
| Page | ||
|---|---|---|
| Charity information | 1 | |
| Members' Annual Report | 1 | |
| Statement of Members' responsibilities | 4 | |
| Independent Accountant's Report | 7 | |
| Statement of Financial Activities | 8 | |
| Balance sheet | 10 | |
| Notes to the accounts | 11 |
British Psoriatic Arthritis Consortium
Members' Annual Report for the year ended 31 March 2024
The Members present their Report and Accounts for the year ended 31 March 2024.
Reference and administrative details
The charity name
The legal name of the charity is:- British Psoriatic Arthritis Consortium.
The charity is also known by its operating name, Brit-PACT.
The charity's areas operation and UK charitable registration
The charity is registered in England & Wales with the Charity Commission in England & Wales (CCEW) with charity number 1189246.
The charity does not operate in any overseas jurisdictions.
Legal structure of the charity
The charity is constituted as a Charitable Incorporated Organisation (CIO) in England & Wales. The governing document of the charity is the constitution of the CIO as approved by the Charity Commission in England & Wales (CCEW) .
The governing document is dated 20 April 2020 There are no restrictions in the governing documents on the operation of the Charity or on its investment powers other than those imposed by Charity Law.
The trustees are all individuals.
The principal operating address and website of the charity are:-
Department D1, Wolfson Building Royal United Hospital, Combe Park Bath, BA1 3NG
www.britpact.org.uk
The Members in office on the date the report was approved were:-
L Coates N Gullick P Helliwell D Jadon (resigned 17/11/2023) J Packham W Tillet (resigned 24/11/2023) M Turfrey (resigned 24/11/2023) T Gudu C Allen P Ho A Kelly S Mukherjee L Hailey H Jethwa (resigned 24/11/2023) R Hum (appointed 24/11/2023) H Johsson (appointed 24/11/2023) J Bluett (appointed 24/11/2023)
The following persons served as Members during the year ended 31 March 2024 :-
The members who served as a member in the reporting period were as shown above, and there were no changes during the year, or in the period between the year end and the approval of the accounts.
1
British Psoriatic Arthritis Consortium
Members' Annual Report for the year ended 31 March 2024
Objects and activities of the charity
The purposes of the charity as set out in its governing document
The object of the CIO is to relieve sickness and to preserve and protect good health for the public benefit by promoting medical knowledge, and excellence through education and research with particular reference to the diseases of psoriasis and psoriatic arthritis.
The main activities undertaken in relation to those purposes during the year
In this financial year, Brit-PACT continues to progress in its mission to support education and research into psoriatic arthritis (PsA) in the UK.
We held a successful annual meeting in hybrid format in November 2023 which was arranged by Dr Sandeep Mukherjee & Louise Hailey, and chaired by Dr Sandeep Mukherjee and Professor Laura Coates. 28 delegates attended in person, and 12 online.
Meeting highlights included a presentation on Wellbeing in Psoriatic arthritis from Professor Chris Bundy and an Update on Psoriatic Disease by Laura Savage, with presentations from Research and Clinical Abstract Prize Winners and Runners up. The remaining submitted abstracts were presented as posters. The winners of the Pilot research project grants in 2023 were invited to present an update on their research. Presentations from our patient partners were well received.
A second annual pilot research grant scheme was announced at the Annual meeting in 2023, and a single grant awarded to a researcher at the University of Manchester in early 2024. All grants submitted were asked to include at least one of the ‘Top 10’ items identified in the James Lind Priority Setting Partnership, which had been funded and published previously by Brit-PACT.
We have continued to support other research with external funding. Brit-PACTs main project in 2023-4 was the SEQUENCE study, with data collection across multiple Brit-PACT sites being completed in October 2024. Data analysis is ongoing.
Brit-PACT continues to provide support and updates to the British Society for Rheumatology on its activities and provides support to subcommittees of the BSR such as recommendations for biologic use in psoriatic arthritis.
The main activities undertaken during the year to further the charity's purpose for the public benefit.
As in previous years the main activities of BritPACT during the last year were educational meetings and the launch of pilot research grants and BritPACT-led research projects, both of which fulfilled the purpose of the charity and will be of benefit the charity’s beneficiaries. Members of the Executive Committee and took part in an external project to create consensus recommendations for diagnosis, assessment and management of psoriatic arthritis, including its comorbidities. These recommendations also were reviewed by representatives from the BritPACT patient group. These were presented at an international rheumatology conference in June 2023 and a publication is in progress.
The trustees have had regard to the Charity Commission's guidance on public benefit in managing the activities of the charity.
2
British Psoriatic Arthritis Consortium
Members' Annual Report for the year ended 31 March 2024
The main achievements and performance of the charity during the year
- Psoriatic Arthritis Education for Health Care Professionals
Brit-PACT continues to conduct educational meetings for rheumatology health care professionals and seeks to grow membership with a wider spectrum of HCPs, including dermatologists and allied health professionals. Our main educational event was the Annual meeting in November 2023. An update on behalf of the Charity was also presented as part of the Spondyloarthritis Special Interest Group at the British Society for Rheumatology Annual Conference in April 2023.
- Funding and supporting Psoriatic Arthritis Research
Brit-PACT has funded 2 pilot research projects during 2024, supporting small projects which aim to answer research questions relevant to patients with PsA. These were awarded to Dr Dylan McGagh (University of Oxford) and Dr Ryan Hum (University of Manchester). Project updates were presented to the membership at the Annual meeting. A 3rd Pilot grant was awarded in early 2024 to Dr Steven Zhao (University of Manchester).
Through obtaining external funding, Brit-PACT has run the SEQUENCE project to collect on use of high cost treatments for Psoriatic Arthritis in Rheumatology Departments across the UK, with high engagement from the general Brit-PACT membership. Data collection was completed in October 2023 and analysis is in progress.
- Involvement in consensus recommendations for diagnosis, assessment and management of psoriatic arthritis
Members of the Executive Committee and took part in an external project to create consensus recommendations for diagnosis, assessment and management of psoriatic arthritis, including its comorbidities. These recommendations also were reviewed by representatives from the wider Brit-PACT patient group. These were published in Rheumatology in early 2024.
- Sharing patient perspective on living with psoriatic disease.
The difference the charity's performance during the year has made to the beneficiaries of the charity
Brit-PACT educational updates and virtual meetings provide educational opportunities for rheumatologists in training and rheumatology teams in the UK. The Brit-PACT patient partners also benefit
from these educational activities as well as providing support to others both in person and electronically. Involvement in the consensus recommendations for diagnosis, assessment and management of psoriatic arthritis should enable rheumatologists to improve services for patients with PsA in both primary and secondary care.
The degree to which the achievements and performance during the year have benefited wider society.
The results of the PsA James Lind Priority Setting Partnership “Top 10” is now being used to feed into grant proposals so that research prioritises area important to clinicians, patients and carers. The JLPSP will continue to help both researchers and funders to prioritise research in this area and help prevent the impact of psoriatic arthritis on patients, carers, and employers, as well as to raise the profile of psoriatic arthritis from a societal point of view.
The patient partners continue to share the patient perspective with Clinicians & HCPs and collaborate with other organisations to inform research direction. The patient partners have started work on a new patient led e-survey
investigating the patient experience of non-pharmacological therapies, and this work is ongoing. Patient partners continue to be involved in research projects and the development of published papers about the condition. Alongside these opportunities to advocate and inform patient material where applicable continues.
3
British Psoriatic Arthritis Consortium
Members' Annual Report for the year ended 31 March 2024
Structure, governance and management of the charity
The methods used to recruit and appoint new charity trustees.
The Brit-PACT constitution incorporates elections for major Executive committee positions. The Executive Committee (trustees) includes rheumatologists in training, allied health professionals and patient partners. In line with the constitution of the Charity nominations are sought annually for new Executive committee members as vacancies become available, and voting is by a single vote of all members, the majority vote taken as the definitive result. In this calendar year there have been 4 retirements from the Executive (Dr Deepak Jadon, Dr Hannah Jethwa, Dr William Tillett, Ms Mel Turfrey) and new medical members elected (Dr James Bluett, consultant and clinical academic), and two trainee representatives (Dr Hanna Johnsson & Dr Ryan Hum).
Bankers Unity Trust Bank, 4 Brindley Place, Birmingham B1 2JB Solicitors Stone King LLP, 13 Queen Square, Bath BA1 2HJ Accountants DR Hicks, 107 Penn Hill Road, Bath BA1 3RU
Financial review
The charity's financial position at the end of the year ended 31 March 2024
The financial position of the charity at 31 March 2024 and comparatives for the prior period, as more fully detailed in the accounts, can be summarised as follows:-
| Restricted Revenue Funds Total Funds Unrestricted Revenue Funds available for the general purposes of the charity Net income |
2024 £ (87,339) 112,649 59,698 172,347 |
2023 £ 79,184 |
|---|---|---|
| 131,938 127,748 |
||
| 259,686 |
Financial review of the position at the reporting date 31 March 2024
The members consider the financial performance by the charity during the year to have been satisfactory.
Policies on reserves
The board of trustees agree to run the charity with reserves sufficient to meet expenses for approximately one year.
Availability and adequacy of assets of each of the funds
The board of trustees is satisfied that the charity's assets in each fund are available and adequate to fulfil its obligations in respect of each fund.
4
British Psoriatic Arthritis Consortium
Members' Annual Report for the year ended 31 March 2024
Details of The Independent Examiner
Dione Hicks
Member of the Institute of Chartered Accountants in England & Wales 107 Penn Hill Road
Bath
BA1 3RU
Statement of Members' Responsibilities
The charity's trustees are responsible for the preparation of the accounts in accordance with the terms of the Charities Act 2011 and the Charities (Accounts and Reports) Regulations 2008. Notwithstanding the explicit requirement in the extant statutory regulations,the Charities (Accounts and Reports) Regulations 2008, to prepare the financial statements in accordance with the SORP 2005, in view of the fact that the SORP 2005 has been withdrawn, the Members determined to interpret this responsibility as requiring them to follow current best practice and prepare the accounts according to the FRS 102 SORP (Statement of Recommended Practice for Accounting and Reporting by Charities) 2015, (as amended by the Bulletin issued in October 2018 and applicable to all accounting periods beginning on or after 1st January 2019), (The SORP), .
In particular, charity law requires the Members, if they prepare accounts on an accruals basis, to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the charity as at the end of the financial year and of the surplus or deficit of the charity. In preparing those financial statements the Members are required to :-
-
to prepare the accounts in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards and applicable law).
-
select suitable accounting policies and apply them consistently;
-
make judgements and estimates that are reasonable and prudent;
-
prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charity will continue in business;
-
state whether applicable accounting standards and statements of
recommended practice have been followed, subject to any material
departures disclosed and explained in the financial statements;
The law requires that the trustees must not approve the accounts unless they are satisfied that they give a true and fair view of the state of affairs of the charity and of the surplus or deficit of the charity for the year.
The Members are also responsible for maintaining adequate accounting records which disclose with reasonable accuracy at any time the financial position of the charity and which are sufficient to show and explain the charity's transactions and enable them to ensure that the financial statements comply with regulations made under the Charities Act 2011. They are also responsible for safeguarding the assets of the charity and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.
The Members are also responsible for the contents of the Members' report, and the statutory responsibility of the Independent Examiner in relation to the Members' report is limited to examining the report and ensuring that , on the face of the report, there are no material inconsistencies with the figures disclosed in the financial statements.
5
British Psoriatic Arthritis Consortium
Members' Annual Report for the year ended 31 March 2024
This report was approved by the board of trustees on 26 November 2024.
P Helliwell Trustee
6
British Psoriatic Arthritis Consortium
Report of the Independent Examiner to the Members of the charity on the accounts for the year ended 31 March 2024
I report to the Members on my examination of the financial statements of the charity on pages 9 to 18 for the year ended 31 March 2024 which have been prepared in accordance with the Charities Act 2011 (the Act) and with the Financial Reporting Standard 102, (effective 1st January 2016) as modified by FRS 102 SORP (Statement of Recommended Practice for Accounting and Reporting by Charities) 2015, (as amended by the Bulletin issued in October 2018 and applicable to all accounting periods beginning on or after 1st January 2019), (The SORP), published by the Charity Commission in England & Wales (CCEW) , and under the historical cost convention and the accounting policies set out on page 11.
Respective responsibilities of the Members and the Independent Examiner and the basis of the report
As described on page 4, you, the charity's Members, are responsible for the preparation of the financial statements in accordance with the Charities Act 2011 and all other applicable law and with United Kingdom Generally Accepted Accounting Practice, applicable to smaller entities, and for being satisfied that the financial statements give a true and fair view.
The Members consider that the audit requirement of Section 144(1) of the Charities Act 2011 (the Act) does not apply, and that there is no requirement in the Governing Document for the conducting of an audit. As a consequence, the Members have elected that the financial statements be subject to independent examination.
Having satisfied myself that the financial statements are not required to be audited under any legal provision, or otherwise, and are eligible for independent examination, it is my responsibility to:-
a) examine the financial statements of the charity under Section 145 of the Act;
b) follow the applicable procedures in the Directions given by the Charity Commission under section 145(5)(b) of the Act.
Basis of Independent Examiner's Statement and scope of work undertaken
I report in respect of my examination of the charity's financial statements carried out under s145 of the Act. In carrying out my examination, I have followed all the applicable Directions given by the Charity Commission under section 145(5)(b) of the Act setting out the duties of an independent examiner in relation to the conducting of an independent examination. An independent examination includes a review of the accounting records kept by the charity and of the accounting systems employed by the charity and a comparison of the financial statements presented with those records. It also includes consideration of any unusual items or disclosures in the financial statements, and seeking explanations from you, as Members, concerning such matters. The purpose of the examination is to establish as far as possible that there have been no breaches of charity legislation and that, on a test basis of evidence relevant to the amounts and disclosures made, the financial statements comply with the SORP.
The procedures undertaken do not provide all the evidence that would be required in an audit, and information supplied by the Members in the course of the examination is not subjected to audit tests or enquiries and does not cover all the matters that an auditor would consider in arriving at an opinion. The planning and conduct of an audit goes beyond the limited assurance that an independent examination can provide
Consequently, I do not express an audit opinion on the view given by the financial statements, and in particular, I express no opinion as to whether the financial statements give a true and fair view of the affairs of the charity, and my report is limited to the matters set out in the statement below.
I planned and performed my examination so as to satisfy myself that the objectives of the independent examination are achieved and before finalising the report I obtained written assurances from the Members of all material matters.
Independent Examiner's Statement, Report and Opinion
Subject to the limitations upon the scope of my work as detailed above, I have completed my examination: and can confirm that:-
7
British Psoriatic Arthritis Consortium
This is a report in respect of an examination carried out under 145 of the Act and in accordance with Directions given by the Charity Commission under section 145(5)(b) of the Act which may be applicable;
and that no material matters have come to my attention in connection with the examination giving me cause to believe that in any material respect:-
accounting records were not kept in respect of the charity as required by with Section 130 of The Charities Act 2011;
the financial statements do not accord with those records; or
the financial statements do not comply with the applicable requirements concerning the form and content of accounts set out in the Charities (Accounts and Reports) Regulations 2008 other than any requirement that the accounts give a 'true and fair' view, which is not a matter considered as part of an independent examination;
have not been prepared in accordance with the methods and principles set out in the FRS 102 SORP (Statement of Recommended Practice for Accounting and Reporting by Charities) 2015, (as amended by the Bulletin issued in October 2018 and applicable to all accounting periods beginning on or after 1st January 2019), (The SORP).
I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the financial statements to be reached.
Signed:-
Dione Hicks - Independent Examiner
Chartered Accountants 107 Penn Hill Road Bath BA1 3RU
This report was signed on 26 November 2024
8
British Psoriatic Arthritis Consortium
Statement of Financial Activities for the year ended 31 March 2024
| Current year Unrestricted Funds 2024 £ Income & Endowments from: Donations & Legacies A1 43,353 Investments A4 212 Total income A 43,565 Expenditure on: Charitable activities B2 62,854 Total expenditure B 62,854 Net income for the year (19,289) Net income after transfers A-B-C (19,289) (19,289) Reconciliation of funds:- E Total funds brought forward 131,938 Total funds carried forward 112,649 SORP Ref Net movement in funds |
Current year Restricted Funds 2024 £ - - - 68,050 68,050 (68,050) (68,050) (68,050) 127,748 59,698 |
Current year Total Funds 2024 £ 43,353 212 43,565 130,904 130,904 (87,339) (87,339) (87,339) 259,686 172,347 |
Prior Year Total Funds 2023 £ 146,630 99 |
|---|---|---|---|
| 146,729 | |||
| 67,545 | |||
| 67,545 | |||
| 79,184 | |||
| 79,184 | |||
| 79,184 180,502 |
|||
| 259,686 |
The 'SORP Ref' indicated above is the classification of income set out in the formal SORP documents. As required by paragraph 4.60 of the SORP, the brought forward and carried forward funds above have been agreed to the Balance Sheet.
A separate Statement of Total Recognised Gains and Losses is not required as this statement includes all recognised gains and losses.
All the prior year transactions were unrestricted items, and no further analysis is required
All activities derive from continuing operations
The notes attached on pages 11 to 18 form an integral part of these accounts.
9
British Psoriatic Arthritis Consortium
Balance Sheet as at 31 March 2024
| SORP | ||||||
|---|---|---|---|---|---|---|
| Note | Ref | 2024 | 2023 | |||
| £ | £ | |||||
| Current assets | B | |||||
| Debtors | 6 | B2 | - | 853 | ||
| Cash at bank and in hand | B4 | 194,994 | 262,116 | |||
| Total current assets | 194,994 | 262,969 | ||||
| Creditors: amounts falling due within | ||||||
| one year | 7 | C1 | (22,647) | (3,283) | ||
| Net current assets | 172,347 | 259,686 | ||||
| The total net assets of the charity | 172,347 | 259,686 | ||||
| The total net assets of the charity are | funded by the funds of the charity, as follows:- | |||||
| Restricted funds | ||||||
| Restricted Revenue Funds | 11 | D2 | 59,698 | 127,748 | ||
| 59,698 | 127,748 | |||||
| Unrestricted Funds | ||||||
| Unrestricted Revenue Funds | 11 | D3 | 112,649 | 131,938 | ||
| 112,649 | 131,938 | |||||
| Designated Funds | ||||||
| Total charity funds | 172,347 | 259,686 |
The 'SORP Ref' indicated above is the classification of Balance Sheet items as set out in the formal SORP documents. As required by paragraph 4.60 of the SORP, the brought forward and carried forward funds above have been agreed to the SOFA..
The Members acknowledge their responsibilities for complying with the requirements of charity legislation with res
The charity is subject to Independent Examination under charity legislation, and the report of the Independent Examiner is on page 8.
The Members are satisfied that, although the charity is not registered under the Companies Acts, if it were so registered, it would be eligible to prepare accounts in accordance with the provisions in Part 15 of the Companies Act 2006. applicable to companies subject to the small companies regime.
P Helliwell
Trustee
Approved by the board of trustees on 26 November 2024
The notes attached on pages 11 to 18 form an integral part of these accounts.
10
British Psoriatic Arthritis Consortium
Notes to the Accounts for the year ended 31 March 2024
1 Accounting policies
Policies relating to the production of the accounts.
Basis of preparation and accounting convention
The accounts have been prepared on the accruals basis, under the historical cost convention, and in accordance with the Financial Reporting Standard 102, (effective 1st January 2016) and 'FRS 102 SORP (Statement of Recommended Practice for Accounting and Reporting by Charities) 2015, (as amended by the Bulletin issued in October 2018 and applicable to all accounting periods beginning on or after 1st January 2019), (The SORP), published by the Charity Commission in England & Wales (CCEW) , effective January 2016, , and in accordance with all applicable law in the charity's jurisdiction of registration, except that the charity has prepared the financial statements in accordance with the FRS 102 SORP (Statement of Recommended Practice for Accounting and Reporting by Charities) 2015, (as amended by the Bulletin issued in October 2018 and applicable to all accounting periods beginning on or after 1st January 2019), (The SORP), in preference to the previous SORP, the SORP 2005, which has been withdrawn, notwithstanding the fact that the extant statutory regulations, the Charities (Accounts and Reports) Regulations 2008 refer explicitly to the SORP 2005. This has been done to accord with current best practice.
Going Concern
Under 3.38 and to comply with 3.14, if there are no uncertainties about going concern this MUST be stated. Under 3.39, if there are uncertainties details must be given. Enter text here to comply
Suggested normal text (whioch may require modification to meet the circumstances):-
The charitable activities are entirely dependent on continuing grant aid and voluntary donations as well as trading revenues. As a consequence, the going concern basis is dependent on the future flow of these uncertain funding streams. Accordingly, the Trustees have obtained forecasts and, after reviewing the financial forecasts for future periods to 31 March 2021, the Trustees are satisfied that, at the time of approving the financial statements, it is appropriate to adopt the going concern basis in preparing the financial statements. Other than these matters, the Trustees are not aware of any material uncertainites about the charity's ability to continue as a going concern.
Risks and future assumptions
The charity is a public benefit entity.
Policies relating to categories of income and income recognition.
Nature of income
Gross income represents the value, net of value added tax and discounts, of goods provided to customers and work carried out in respect of services provided to customers.
Categories of Income
Income is categorised as income from exchange transactions (contract income) and income from non-exchange transactions (gifts), investment income and other income.
Income from exchange transactions is received by the charity for goods or services supplied under contract or where entitlement is subject to fulfilling performance related conditions. The income the charity receives is approximately equal in value to the goods or services supplied by the charity to the purchaser.
Income from a non-exchange transaction is where the charity receives value from the donor without providing equal value in exchange, and includes donations of money, goods and services freely given without giving equal value in exchange.
11
British Psoriatic Arthritis Consortium
Notes to the Accounts for the year ended 31 March 2024
Income recognition
Income, whether from exchange or non exchange transactions, is recognised in the statement of financial activities (SOFA) on a receivable basis, when a transaction or other event results in an increase in the charity’s assets or a reduction in its liabilities and only when the charity has legal entitlement, the income is probable and can be measured reliably.
Dividends are accrued when the shareholder’s right to receive payment is established.
Income subject to terms and conditions which must be met before the charity is entitled to the resources is not recognised until the conditions have been met.
All income is accounted for gross, before deducting any related fees or costs.
Policies relating to expenditure on goods and services provided to the charity.
Recognition of liabilities and expenditure
A liability, and the related expenditure, is recognised when a legal or constructive obligation exists as a result of a past event, and when it is more likely than not that a transfer of economic benefits will be required in settlement, and when the amount of the obligation can be measured or reliably estimated..
Liabilities arising from future funding commitments and constructive obligations, including performance related grants, where the timing or the amount of the future expenditure required to settle the obligation are uncertain, give rise to a provision in the accounts, which is reviewed at the accounting year end. The provision is increased to reflect any increases in liabilities, and is decreased by the utilisation of any provision within the period, and reversed if any provision is no longer required. These movements are charged or credited to the respective funds and activities to which the provision relates.
Policies relating to assets, liabilities and provisions and other matters.
Debtors
Debtors are measured at their recoverable amounts at the balance sheet date.
Creditors and provisions
Creditors and provisions are measured at their recoverable amounts at the balance sheet date.
Cash and bank balances
Cash held by the charity is included at the amount actually held and counted at the year end. Bank balances, whether in credit or overdrawn, are shown at the amounts properly reconciled to the bank statements.
Fund Accounting
Unrestricted funds are available for use at the discretion of the trustees in furtherance of the general objectives of the charity.
There are no designated funds.
Restricted funds are subjected to restrictions on their expenditure imposed by the donor or through the terms of an appeal or as implied by law.
There are no endowment funds.
12
British Psoriatic Arthritis Consortium
Notes to the Accounts for the year ended 31 March 2024
2 Liability to taxation
The Trustees consider that the charity satisfies the tests set out in Paragraph 1 Schedule 6 of the Finance Act 2010 for UK corporation tax purposes. Accordingly, the Charity is potentially exempt from taxation in respect of income or capital gains received within categories covered by chapter 3 part 11 of the Corporation Tax Act 2010 or Section 256 of the Taxation of Chargeable Gains Act 1992, to the extent that such income or gains are applied exclusively on the specific charitable objects of the charity and for no other purpose. Value Added Tax is not recoverable by the charity, and is therefore included in the relevant costs in the Statement of Financial Activities.
3 Winding up or dissolution of the charity
If upon winding up or dissolution of the charity there remain any assets, after the satisfaction of all debts and liabilities, the assets represented by the accumulated fund shall be transferred to some other charitable body or bodies having similar objects to the charity.
4 Significance of financial instruments to the charity's position
There are no significant implications of financial instruments to the Charity's positon.
5 Remuneration and payments to Trustees and persons connected with them
No trustees or persons connected with them received any remuneration from the charity, or any related entity.
6 Debtors
| Prepayments and accrued income 7 Creditors: amounts falling due within one year Trade creditors 8 Income and Expenditure account summary At 1 April 2023 Surplus for the year At 31 March 2024 |
2024 2023 £ £ - 853 2024 2023 £ £ 22,647 3,283 2024 2023 £ £ 259,686 180,502 (87,339) 79,184 |
|---|---|
| 172,347 259,686 |
9 No related party transactions
There were no transactions with related parties in the year.
13
British Psoriatic Arthritis Consortium
Notes to the Accounts for the year ended 31 March 2024
10 Particulars of how particular funds are represented by assets and liabilities
| At 31 March 2024 Current Assets Current Liabilities At 1 April 2023 Current Assets Current Liabilities |
Unrestricted funds £ 135,296 (22,647) |
Designated funds £ - |
Restricted Total Total funds Funds Funds £ £ £ 59,698 194,994 194,994 - (22,647) (22,647) |
|---|---|---|---|
| 112,649 | - | 59,698 172,347 172,347 |
|
| Unrestricted funds £ 135,221 (3,283) |
Designated funds £ - - |
Restricted Total Total funds Funds Funds £ £ £ 127,748 262,969 262,969 - (3,283) (3,283) |
|
| 131,938 | - | 127,748 259,686 259,686 |
11 Change in total funds over the year as shown in Note 10 , analysed by individual funds
| Unrestricted and designated funds:- Unrestricted Revenue Funds Total unrestricted and designated funds Restricted funds:- Sequence Project Total restricted funds Total charity funds |
Funds brought forward from 2023 £ 131,938 |
Movement in funds in 2024 See Note 12 £ (19,289) |
Funds carried forward to 2025 £ £ £ - 112,649 112,649 Funds carried forward to 2025 Transfers between funds in 2024 |
|---|---|---|---|
| 131,938 | (19,289) | - 112,649 112,649 |
|
| 127,748 | (68,050) | - 59,698 59,698 |
|
| 127,748 | (68,050) | - 59,698 59,698 |
|
| 259,686 | (87,339) | - 172,347 172,347 |
14
British Psoriatic Arthritis Consortium
Notes to the Accounts for the year ended 31 March 2024
12 Analysis of movements in funds over the year as shown in Note 11
| Unrestricted and designated funds:- Unrestricted Revenue Funds Restricted funds:- Sequence Project |
Income 2024 £ 43,565 - |
Expenditure 2024 £ (62,854) (68,050) |
Other Gains & Movement Movement Losses in funds in funds 2024 2024 2024 £ £ £ - (19,289) (19,289) - (68,050) (68,050) |
|---|---|---|---|
| 43,565 | (130,904) | - (87,339) (87,339) |
13 The purposes for which the funds as detailed in note 11 are held by the charity Unrestricted and designated funds:-
Unrestricted Revenue Funds
These funds are held for the meeting the objectives of the charity, and to provide reserves for future activities, and , subject to charity legislation, are free from all restrictions on their use.
Designated Revenue Funds
There are no such funds held by the Charity.
Restricted funds:-
Restricted Revenue Funds
Funds specific for this pupose.
14 Ultimate controlling party
The charity is under the control of its legal members.
If the CIO is wound up, the members of the CIO have no liability to contribute to its assets and no personal responsibility for settling its debts and liabilities.
15
British Psoriatic Arthritis Consortium
Detailed analysis of income and expenditure for the year ended 31 March 2024 as required by the SORP 2015
This analysis is classsified by conventional nominal descriptions and not by activity.
15 Donations, Grants and Legacies
Donations and gifts from individuals Small donations individually less than £1000 Total donations and gifts from individuals
| Current year Unrestricted Funds 2024 £ 853 |
Current year Restricted Funds 2024 £ - - |
Current year Total Funds 2024 £ 853 853 |
Prior Year Total Funds 2023 £ 256 |
|---|---|---|---|
| 853 | 256 |
| Total private sector revenue grants Revenue grants and donations from non public bodies Pfizer Eli Lilly |
Current year Unrestricted Funds 2024 £ - - |
Current year Restricted Funds 2024 £ - - - |
Current year Total Funds 2024 £ - - - |
Prior Year Total Funds 2023 £ 43,187 43,187 |
|---|---|---|---|---|
| - | 86,374 |
| Total Donations, Grants and Legacies A1 Novartis Total sponsorship income UCB Lilly Sterling University Janssen-Claig Ltd BMS Abbvie Ltd |
Current year Unrestricted Funds 2024 £ - 10,000 10,000 15,000 7,500 - - |
Current year Restricted Funds 2024 £ - - - - - - - - |
Current year Total Funds 2024 £ - 10,000 10,000 15,000 7,500 - - 42,500 |
Prior Year Total Funds 2023 £ 10,000 10,000 10,000 10,000 - 10,000 10,000 |
|---|---|---|---|---|
| 42,500 | 60,000 | |||
| 43,353 | - | 43,353 | 146,630 |
16
British Psoriatic Arthritis Consortium
Detailed analysis of income and expenditure for the year ended 31 March 2024 as required by the SORP 2015
| 16 Investment income Current year Current year Unrestricted Funds Restricted Funds 2024 2024 £ £ Bank Interest Receivable 212 - Total investment income A4 212 - 17 Expenditure on charitable activities - Direct spending Current year Current year Current Year Unrestricted Funds Restricted Funds 2024 2024 £ £ 4,469 - 600 - 1,400 - 10,374 - (10,000) 68,050 Total direct spending B2a 6,843 68,050 18 Expenditure on charitable activities- Grant funding of activities Current year Current year Current Year Unrestricted Funds Restricted Funds 2024 2024 £ £ 50,000 - Total grantmaking costs B2c 50,000 - 19 Current year Current year Current Year Unrestricted Funds Restricted Funds 2024 2024 £ £ Premises Expenses 1,850 - Administrative overheads 224 - Sequence project expenses Administration fees Abstract award Course expenses Rent payable under operating leases Support costs for charitable activities Grants awarded Telephone and internet Patient Partner expenses |
Current year Total Funds 2024 £ 212 212 Current year Total Funds 2024 £ 4,469 600 1,400 10,374 58,050 74,893 Current year Total Funds 2024 £ 50,000 |
Prior Year Total Funds 2023 £ 99 |
|---|---|---|
| 99 | ||
| Prior Year Total Funds 2023 £ 4,328 600 2,242 9,542 45,000 |
||
| 61,712 | ||
| Prior Year Total Funds 2023 £ |
||
| - | ||
| 50,000 | - | |
| Current year Total Funds 2024 £ 1,850 224 |
Prior Year Total Funds 2023 £ 1,850 216 |
17
British Psoriatic Arthritis Consortium
Detailed analysis of income and expenditure for the year ended 31 March 2024 as required by the SORP 2015
| Financial costs Support costs before reallocation Total support costs Bank charges Stationery and printing Insurance Subscriptions IT support and costs Bookkeeping fees Sundry expenses |
243 158 932 368 47 756 72 |
- - - - - - - - - |
243 158 932 368 47 756 72 |
138 150 608 293 10 830 96 |
|---|---|---|---|---|
| 4,650 | 4,650 4,650 |
4,191 | ||
| 4,650 | 4,191 | |||
| ~~-~~ |
All the expenditure in the prior year was unrestricted.
20 Other Expenditure - Governance costs
| Current Year Independent Examiner's fees Total Governance costs |
Current year Unrestricted Funds 2024 £ 1,361 |
Current year Restricted Funds 2024 £ - - |
Current year Total Funds 2024 £ 1,361 1,361 |
Prior Year Total Funds 2023 £ 1,642 |
|---|---|---|---|---|
| 1,361 | 1,642 |
All the expenditure in the prior year was unrestricted.
21 Total Charitable expenditure
| Current Year Total direct spending B2a Total grantmaking costs B2c Total support costs B2d Total Governance costs B2e Total charitable expenditure B2 |
Current year Unrestricted Funds 2024 £ 6,843 50,000 4,650 1,361 |
Current year Restricted Funds 2024 £ 68,050 - - - 68,050 |
Current year Total Funds 2024 £ 74,893 50,000 4,650 1,361 130,904 |
Prior Year Total Funds 2023 £ 61,712 - 4,191 1,642 |
|---|---|---|---|---|
| 62,854 | 67,545 |
All the expenditure in the prior year was unrestricted.
| Prior Year Total direct spending B2a Total support costs B2d Total Governance costs B2e Total charitable expenditure B2 |
Prior Year Unrestricted Funds 2023 £ 61,712 4,191 1,642 |
Prior Year Prior Year Restricted Funds Total Funds 2023 2023 £ £ - 61,712 - 4,191 - 1,642 |
|---|---|---|
| 67,545 | - 67,545 |
18